Search - tctmd.com

Displaying 1 - 20 of 722

Sort: Relevancy | Date

Despite Guidelines, Aspirin Is Used in Fewer Than One in Four High-risk Pregnancies

News Conference News ACC 2026

Despite Guidelines, Aspirin Is Used in Fewer Than One in Four High-risk Pregnancies

Yael L. Maxwell

April 03, 2026

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

News Conference News ACC 2026

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

Yael L. Maxwell

April 01, 2026

GoFreshRx, THRIVE Trials Show BP Benefits of ‘Food as Medicine’

News Conference News ACC 2026

GoFreshRx, THRIVE Trials Show BP Benefits of ‘Food as Medicine’

March 31, 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

News Conference News ACC 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

Michael O'Riordan

March 30, 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

KARDINAL: Monthly Tonlamarsen May Not Enhance BP Lowering in Resistant Hypertension

News Conference News ACC 2026

KARDINAL: Monthly Tonlamarsen May Not Enhance BP Lowering in Resistant Hypertension

March 28, 2026

What’s Going to Be Hot at ACC 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

PARTNER 3: TAVI and SAVR Matched for Health Status at 7 Years

News Conference News CRT 2026

PARTNER 3: TAVI and SAVR Matched for Health Status at 7 Years

March 17, 2026

DOBERMANN: Dobutamine and Tocilizumab Show Promise in Pre-Shock Patients

News Conference News CRT 2026

DOBERMANN: Dobutamine and Tocilizumab Show Promise in Pre-Shock Patients

March 09, 2026

Loberamisal Scores a Rare Win for Stroke Neuroprotection

News Conference News ISC 2026

Loberamisal Scores a Rare Win for Stroke Neuroprotection

February 12, 2026

OPTION: IV Tenecteplase Boosts Outcomes Late After Non-LVO Stroke

News Conference News ISC 2026

OPTION: IV Tenecteplase Boosts Outcomes Late After Non-LVO Stroke

February 11, 2026

OCEANIC-STROKE: Asundexian Prevents Recurrent Strokes, With No Added Bleeding

News Conference News ISC 2026

OCEANIC-STROKE: Asundexian Prevents Recurrent Strokes, With No Added Bleeding

February 09, 2026

CHOICE-2 Bolsters Intra-arterial Lytics After Stroke Thrombectomy

News Conference News ISC 2026

CHOICE-2 Bolsters Intra-arterial Lytics After Stroke Thrombectomy

February 06, 2026

FASTEST Hints at Benefits of Hemostatic Therapy for Acute ICH in Select Groups

News Conference News ISC 2026

FASTEST Hints at Benefits of Hemostatic Therapy for Acute ICH in Select Groups

February 05, 2026

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

News Conference News AHA 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Michael O'Riordan

November 10, 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

November 03, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.